← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Novartis NVS $279B	1,136	-41	-3%	$18.7B
2	2 Charles River Laboratories CRL $14.4B	561	+22	+4%	$13.7B
3	3 DELISTED CATALENT, INC. CTLT	500	-7	-1%	$17.6B
4	4 CRISPR Therapeutics CRSP $4.86B	444	+32	+8%	$5.2B
5	5 Sarepta Therapeutics SRPT $1.78B	367	-88	-19%	$4.97B
6	6 Intellia Therapeutics NTLA $1.6B	261	+20	+8%	$5.07B
7	7 Fate Therapeutics FATE $232M	260	+12	+5%	$7.73B
8	8 Ultragenyx Pharmaceutical RARE $1.47B	255	+2	+0.8%	$7.73B
9	9 DELISTED bluebird bio BLUE	229	-33	-13%	$1.58B
10	10 PTC Therapeutics PTCT $4.98B	208	-7	-3%	$3.52B
11	11 Vericel Corp VCEL $2.06B	205	+35	+21%	$2.75B
12	12 DELISTED SANGAMO THERAPEUTICS INC SGMO	203	-20	-9%	$995M
13	13 BridgeBio Pharma BBIO $12.7B	199	+38	+24%	$8.69B
14	14 Regenxbio RGNX $454M	184	-3	-2%	$1.12B
15	15 Rocket Pharmaceuticals RCKT $243M	173	-4	-2%	$2.75B
16	16 Allogene Therapeutics ALLO $449M	169	+4	+2%	$3.12B
17	17 Precigen PGEN $2.64B	166	+15	+10%	$979M
18	18 uniQure QURE $1.45B	155	-11	-7%	$1.22B
19	19 Atara Biotherapeutics ATRA $96M	151	+3	+2%	$1.24B
20	ATHX 20 DELISTED Athersys, Inc. Common Stock ATHX	139	-1	-0.7%	$108M
21	21 DELISTED BioLife Solutions BLFS	133	+5	+4%	$915M
22	22 DELISTED Adverum Biotechnologies ADVM	132	-23	-15%	$938M
23	23 Lakefront Biotherapeutics American Depositary Shares LKFT $1.93B	132	+16	+14%	$506M
24	TCRR 24 DELISTED TCR2 Therapeutics Inc. Common Stock TCRR	129	+11	+9%	$835M
25	25 Precision BioSciences DTIL $166M	128	+10	+8%	$313M